Nexalis Therapeutics (ASX:NX1) - Insights
ASX:NX1 · Data intelligence from 17 published articles
Total Articles
17
all time
Materiality Rate
100%
of announcements
Signal Strength
Moderate
avg newsworthiness
Positive Tone
13%
of published articles
Publication Activity
Signal Strength Trend
Tone Split
Announcement Types
Impact Profile
Publication Heatmap Sydney time · day × hour
0h6h12h18h
Sun
Mon
Tue
Wed
Thu
Fri
Sat
Less
More
Announcement Signals
How often each theme appears across all enriched announcements for this company.
Capital Impact
High
85% of announcements reference capital raises, buybacks, or funding changes
Legal & Compliance
Moderate
31% of announcements mention regulatory, legal, or compliance matters
Board Changes
None
No board or executive changes detected
Price Guidance
None
No price guidance issued in announcements
Major Contracts
Moderate
15% of announcements reference significant contract wins or losses
Environmental
None
No environmental disclosures detected
IP & Patents
Low
8% of announcements mention intellectual property or patent activity
Research & Data
Moderate
31% of announcements contain research results or clinical/trial data